The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease.

Nat Aging · 2026 · PMC13004677 · PMID 41721133

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

A nominally significant improvement was observed for participants administered the 100-mg dose in the MDS-UPDRS Part II and for the Schwab and England Activities of Daily Living (SEADL) scale for participants administered the 50-mg dose (Table 3 ).

also in 7,732 other papers

did not reach statistical significanceno p-value reported

The primary hierarchical secondary end point of the Movement Disorder Society revision to the Unified PD Rating Scale sum of Parts II + III did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.